PAA.ASX
PharmAust seeks European orphan drug designation for MND/ALS drug monepantel
PharmAust (ASX: PAA) has requested the European Medicines Agency (EMA) grant orphan medicinal product designation (OMPD) for monepantel (MPL), its lead candidate in the treatment of amyotrophic lateral sclerosis (ALS) and motor neurone disease (MND). The OMPD is an EMA initiative to encourage companies to develop safe and effective treatments for rare diseases or neglected […]
PharmAust reports encouraging interim results for ALS/MND drug monepantel in ongoing study
PharmAust (ASX: PAA) has received promising interim results from a major study into monepantel (MPL), its lead amyotrophic lateral sclerosis (ALS) / motor neurone disease (MND) treatment candidate. The clinical-stage biotechnology company revealed that treatment with MPL at 10 milligrams per kilogram of body weight daily continues to be well-tolerated, slowing disease progression and improving […]
PharmAust’s transformative quarter sees monepantel treatment gain ground on MND/ALS
The three months to end June marked a transformative quarter in PharmAust’s (ASX: PAA) focus on monepantel (MPL) for the treatment of neurodegenerative diseases. The company achieved numerous milestones in the development of MPL for motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS). These included the granting of final ethics committee approval for an […]
PharmAust raises $7.8m in oversubscribed SPP to advance monepantel for MND/ALS treatment
PharmAust (ASX: PAA) has raised $7.8 million in a share purchase plan (SPP) to accelerate development of its lead candidate monepantel as a viable treatment for motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS). Shareholder demand for the raising was greater than expected and exceeded the initial target of $2m, with the additional $5.8m […]